Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on investigational therapies for neurodegenerative and endocrine diseases, and its news flow reflects the progress and setbacks typical of clinical-stage drug development. Company updates frequently highlight milestones in its pipeline, including avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 as a long-acting GLP-1 receptor antagonist candidate.
Investors following AMLX news can expect regular announcements on clinical trial progress, such as enrollment status, early safety and tolerability data, and biomarker analyses from studies like the Phase 3 LUCIDITY trial in PBH and the Phase 1 LUMINA trial in ALS. Amylyx also issues press releases when it reports financial results, providing context on research and development spending, cash runway, and the anticipated timing of key clinical and regulatory milestones.
Another recurring news theme is regulatory and program updates, including FDA designations, decisions to advance or discontinue specific programs, and detailed descriptions of conditions such as PBH, ALS, PSP, and Wolfram syndrome. The company has, for example, communicated its decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results, while continuing development of AMX0035 in Wolfram syndrome.
Amylyx also announces capital markets events and investor outreach, such as underwritten public offerings of common stock and participation in healthcare and biopharma conferences. For readers tracking AMLX, this news page offers a consolidated view of clinical, financial, and strategic disclosures that shape the company’s development trajectory. Bookmarking this feed can help investors and observers monitor how Amylyx’ investigational therapies advance through trials and how management communicates key developments.
Amylyx Pharmaceuticals has announced that the FDA is planning to reconvene the Peripheral and Central Nervous System Drugs Advisory Committee to discuss the NDA for AMX0035, a treatment for ALS, on September 7, 2022. This follows the FDA's extension of the PDUFA target action date to September 29, 2022. The meeting will focus on additional analyses from clinical studies, which aim to support the reported benefits of AMX0035. The drug is currently approved for ALS in Canada under the brand name ALBRIOZA.
Amylyx Pharmaceuticals has received its first global regulatory approval from Health Canada for ALBRIOZA™ (AMX0035), a new therapy for amyotrophic lateral sclerosis (ALS) that may reduce neuronal cell death. The approval is based on positive results from the CENTAUR clinical trial, showing significant functional benefits compared to placebo. ALBRIOZA is expected to be commercially available in Canada within six weeks, pending negotiations with local authorities. Further results from the ongoing Phase 3 PHOENIX trial are anticipated in 2024.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS), to September 29, 2022. This extension allows additional time for the FDA to review new data analyses from the company's clinical studies, which was classified as a major amendment to the NDA. The CENTAUR trial, involving 137 participants, demonstrated efficacy in reducing functional decline in ALS patients.
Amylyx Pharmaceuticals announced a new post hoc analysis demonstrating significant individual responses to its drug AMX0035 in ALS patients. The findings will be presented at the ENCALS 2022 Meeting on June 2 in Edinburgh, Scotland. The study revealed a higher proportion of patients in the AMX0035 group exhibiting substantial responses compared to placebo. AMX0035 combines sodium phenylbutyrate and taurursodiol to combat neuronal death in ALS. The CENTAUR trial backing this data confirmed its efficacy and safety.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced new findings from the Phase 2 CENTAUR trial, highlighting significant benefits of AMX0035 in patients with amyotrophic lateral sclerosis (ALS). The treatment reduces the risk of death or tracheostomy/permanent assisted ventilation by 49% and lowers the rate of first hospitalization by 44%. Additionally, participants showed a median key event-free survival duration of 4.8 months longer with AMX0035. These results underscore AMX0035's potential impact on delaying severe medical interventions for ALS patients.
Amylyx Pharmaceuticals (AMLX) is progressing towards the commercial launch of AMX0035 for ALS treatment in the U.S. and Canada, contingent on regulatory approval. Recent Phase 2 trial data published in Muscle & Nerve highlight significant survival benefits of AMX0035. The FDA's PDUFA date is June 29, 2022. Financially, R&D expenses surged to $21.5 million and G&A expenses to $26.4 million in Q1 2022, resulting in a net loss of $47.8 million. However, cash reserves improved to $255.2 million following an IPO in January 2022.
Amylyx Pharmaceuticals has published new long-term survival analyses from the Phase 2 CENTAUR trial for AMX0035 (sodium phenylbutyrate and taurursodiol) in ALS patients. The analysis using the rank-preserving structural failure time model estimated a median survival increase of 10.6 months for AMX0035 participants compared to placebo. In specific subgroups, those who transitioned to the open-label extension phase exhibited an even greater median survival increase of 18.8 months. The results highlight the potential survival benefits of AMX0035 in addressing ALS and are detailed in the peer-reviewed journal Muscle & Nerve.
Amylyx Pharmaceuticals announced data from the CENTAUR and PEGASUS clinical trials, confirming that AMX0035 is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD). The majority of treatment-emergent adverse events (TEAEs) were gastrointestinal, with no new safety signals identified. These findings clarify the safety profile of AMX0035. Participants from both trials reported similar incidences of TEAEs, attributed largely to disease progression in ALS. The data will be presented at the AAN conference on April 4, 2022.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a transformative year in 2021, focusing on the progress of AMX0035 for ALS treatment. The FDA set a PDUFA action date of June 29, 2022. The company successfully submitted regulatory applications in the U.S., Europe, and Canada. Financially, R&D expenses rose to $44 million, while general and administrative expenses reached $38.9 million, resulting in a net loss of $87.9 million for 2021. Despite this, cash reserves significantly improved to $96.1 million, bolstered by a successful IPO that raised $196.9 million in net proceeds.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced the outcome of the FDA's PCNSDAC meeting regarding its NDA for AMX0035, intended for ALS treatment. The advisory committee voted 4 (yes) to 6 (no) on whether the data supports AMX0035's effectiveness. Nonetheless, Amylyx remains confident in the drug's potential and continues to seek FDA approval, which is expected by June 29, 2022. AMX0035 is designed to target pathways involved in neuronal degeneration. The CENTAUR trial met its primary efficacy endpoint, demonstrating a reduction in functional decline.